Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool

Jamal Carter, Li Hui Tseng, Gang Zheng, Jonathan Dudley, Peter B Illei, Christopher Gocke, James Eshleman, Ming-Tseh Lin

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the performance of a next-generation sequencing (NGS) platform for the clinical detection of BRAF mutations. Methods: In this retrospective quality assessment of an NGS assay, we analyzed BRAF mutations within parts of exons 11 and 15 in 835 neoplastic tissues submitted to our molecular diagnostics laboratory. Results: The NGS assays detected a BRAF mutation in 5.9% of lung adenocarcinomas, 13% of colorectal cancers, and 44% of melanomas. Mutant allele frequencies were less than 20% in 28% of 88 BRAF-mutated specimens. Two lymph node specimens with subcapsular or infiltrative metastasis showed 1% to 2% mutant alleles. There were 26 unique BRAF mutations in exons 11 and 15, including three novel mutations. Mutations were located outside codon 600 in 39% of BRAF-mutated tumors. Lung adenocarcinomas showed significantly higher non-p.V600E mutations (86%) than did colorectal cancers (23%) and melanomas (34%). The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mutations (p.D594G [18%], p.V600E [14%], and p.G469A [9%]). Conclusions: The NGS assay demonstrated a high analytic sensitivity and a broad reportable range for clinical detection of BRAF mutations. Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.

Original languageEnglish (US)
Pages (from-to)620-628
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume144
Issue number4
DOIs
StatePublished - Oct 1 2015

Fingerprint

Mutation
Colorectal Neoplasms
Exons
Melanoma
Molecular Pathology
Gene Frequency
Codon
Lung Neoplasms
Neoplasms
Lymph Nodes
Alleles
Neoplasm Metastasis

Keywords

  • BRAF
  • Colorectal cancer
  • Lung cancer
  • Melanoma
  • Next-generation sequencing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool. / Carter, Jamal; Tseng, Li Hui; Zheng, Gang; Dudley, Jonathan; Illei, Peter B; Gocke, Christopher; Eshleman, James; Lin, Ming-Tseh.

In: American Journal of Clinical Pathology, Vol. 144, No. 4, 01.10.2015, p. 620-628.

Research output: Contribution to journalArticle

@article{3091b2031fe448a6a5e608e3f658af0f,
title = "Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool",
abstract = "Objectives: To assess the performance of a next-generation sequencing (NGS) platform for the clinical detection of BRAF mutations. Methods: In this retrospective quality assessment of an NGS assay, we analyzed BRAF mutations within parts of exons 11 and 15 in 835 neoplastic tissues submitted to our molecular diagnostics laboratory. Results: The NGS assays detected a BRAF mutation in 5.9{\%} of lung adenocarcinomas, 13{\%} of colorectal cancers, and 44{\%} of melanomas. Mutant allele frequencies were less than 20{\%} in 28{\%} of 88 BRAF-mutated specimens. Two lymph node specimens with subcapsular or infiltrative metastasis showed 1{\%} to 2{\%} mutant alleles. There were 26 unique BRAF mutations in exons 11 and 15, including three novel mutations. Mutations were located outside codon 600 in 39{\%} of BRAF-mutated tumors. Lung adenocarcinomas showed significantly higher non-p.V600E mutations (86{\%}) than did colorectal cancers (23{\%}) and melanomas (34{\%}). The three most common BRAF mutations in lung cancers accounted for only 41{\%} of the observed BRAF mutations (p.D594G [18{\%}], p.V600E [14{\%}], and p.G469A [9{\%}]). Conclusions: The NGS assay demonstrated a high analytic sensitivity and a broad reportable range for clinical detection of BRAF mutations. Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.",
keywords = "BRAF, Colorectal cancer, Lung cancer, Melanoma, Next-generation sequencing",
author = "Jamal Carter and Tseng, {Li Hui} and Gang Zheng and Jonathan Dudley and Illei, {Peter B} and Christopher Gocke and James Eshleman and Ming-Tseh Lin",
year = "2015",
month = "10",
day = "1",
doi = "10.1309/AJCP85ATMJOZOUDJ",
language = "English (US)",
volume = "144",
pages = "620--628",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool

AU - Carter, Jamal

AU - Tseng, Li Hui

AU - Zheng, Gang

AU - Dudley, Jonathan

AU - Illei, Peter B

AU - Gocke, Christopher

AU - Eshleman, James

AU - Lin, Ming-Tseh

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objectives: To assess the performance of a next-generation sequencing (NGS) platform for the clinical detection of BRAF mutations. Methods: In this retrospective quality assessment of an NGS assay, we analyzed BRAF mutations within parts of exons 11 and 15 in 835 neoplastic tissues submitted to our molecular diagnostics laboratory. Results: The NGS assays detected a BRAF mutation in 5.9% of lung adenocarcinomas, 13% of colorectal cancers, and 44% of melanomas. Mutant allele frequencies were less than 20% in 28% of 88 BRAF-mutated specimens. Two lymph node specimens with subcapsular or infiltrative metastasis showed 1% to 2% mutant alleles. There were 26 unique BRAF mutations in exons 11 and 15, including three novel mutations. Mutations were located outside codon 600 in 39% of BRAF-mutated tumors. Lung adenocarcinomas showed significantly higher non-p.V600E mutations (86%) than did colorectal cancers (23%) and melanomas (34%). The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mutations (p.D594G [18%], p.V600E [14%], and p.G469A [9%]). Conclusions: The NGS assay demonstrated a high analytic sensitivity and a broad reportable range for clinical detection of BRAF mutations. Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.

AB - Objectives: To assess the performance of a next-generation sequencing (NGS) platform for the clinical detection of BRAF mutations. Methods: In this retrospective quality assessment of an NGS assay, we analyzed BRAF mutations within parts of exons 11 and 15 in 835 neoplastic tissues submitted to our molecular diagnostics laboratory. Results: The NGS assays detected a BRAF mutation in 5.9% of lung adenocarcinomas, 13% of colorectal cancers, and 44% of melanomas. Mutant allele frequencies were less than 20% in 28% of 88 BRAF-mutated specimens. Two lymph node specimens with subcapsular or infiltrative metastasis showed 1% to 2% mutant alleles. There were 26 unique BRAF mutations in exons 11 and 15, including three novel mutations. Mutations were located outside codon 600 in 39% of BRAF-mutated tumors. Lung adenocarcinomas showed significantly higher non-p.V600E mutations (86%) than did colorectal cancers (23%) and melanomas (34%). The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mutations (p.D594G [18%], p.V600E [14%], and p.G469A [9%]). Conclusions: The NGS assay demonstrated a high analytic sensitivity and a broad reportable range for clinical detection of BRAF mutations. Elucidating the spectrum of non-p. V600E BRAF mutations in different malignancies is a first step toward understanding their clinical significance.

KW - BRAF

KW - Colorectal cancer

KW - Lung cancer

KW - Melanoma

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=84945145104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945145104&partnerID=8YFLogxK

U2 - 10.1309/AJCP85ATMJOZOUDJ

DO - 10.1309/AJCP85ATMJOZOUDJ

M3 - Article

C2 - 26386083

AN - SCOPUS:84945145104

VL - 144

SP - 620

EP - 628

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -